Novo Nordisk’s Ozempic reduces CKD and cardiovascular risk in Flow trial
In the FLOW clinical trial, which enrolled 3,533 participants with type 2 diabetes and chronic kidney disease (CKD),…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 Mar 24
In the FLOW clinical trial, which enrolled 3,533 participants with type 2 diabetes and chronic kidney disease (CKD),…
05 Mar 24
Acoramidis is an investigational, next-generation, orally administered, highly potent and selective small molecule transthyretin (TTR) stabiliser, intended for…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Mar 24
The FDA approval is based on results from the Phase 3 PAPILLON study, which showed Rybrevant plus chemotherapy…
01 Mar 24
Abrysvo bivalent RSV vaccine showed 77.8% efficacy against RSV-associated LRTD after disease surveillance in season two, and 88.9%…
29 Feb 24
Ginkgo Bioworks has acquired synthetic biology company Patch Biosciences, pharmaceutical company Reverie Labs, and CRISPR-based diagnostic test developer…
29 Feb 24
Under the global licence and collaboration agreement, both firms will advance the French biotech’s OSE-230 to treat chronic…
29 Feb 24
Under the agreement, Viatris will get exclusive global development and commercialisation rights to these assets along with the…
29 Feb 24
Agreement spans wide range of Medidata’s solutions to enhance clinical trial efficiency
28 Feb 24
Biological E will manufacture up to 50 million doses of the Qdenga vaccine annually, advancing Takeda’s ability to…
28 Feb 24
Proceeds from the financing are expected to be used to support Denali’s ongoing research and development activities, the…